
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings Inc demonstrated a robust financial performance, highlighted by a gross margin of 71.1%, marking a 230 basis point increase year-over-year and surpassing market expectations. For 2025, the company maintains a revenue outlook of $870-$880 million, indicating a growth rate of 16-18% year-over-year, complemented by strong contributions from its Zio AT product line and positive trends in pricing and mix. Additionally, iRhythm anticipates annual EBITDA margin improvements of approximately 400 basis points, driven by factors such as increased ambulatory cardiac testing volume, international expansion, and enhanced operational efficiency, positioning the company for sustained profitability.
Bears say
iRhythm Holdings faces a bearish outlook primarily due to anticipated growth slowing to the low-teens, alongside insufficient improvements in profitability. Competitive pressures in the extended-wear cardiac monitoring market, coupled with potential challenges in new product launches like ZioAT, could hinder market traction and limit sales opportunities. Furthermore, rising risks such as negative developments in commercial reimbursements, poor sales execution, and possible equity offerings exacerbate uncertainties regarding the company's financial performance.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares